X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (493) 493
Conference Proceeding (118) 118
Publication (42) 42
Book Review (30) 30
Book / eBook (7) 7
Book Chapter (3) 3
Paper (1) 1
Streaming Audio (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (255) 255
index medicus (219) 219
humans (204) 204
male (146) 146
female (143) 143
aged (135) 135
middle aged (126) 126
colorectal cancer (94) 94
chemotherapy (89) 89
colorectal neoplasms - drug therapy (85) 85
adult (82) 82
antineoplastic combined chemotherapy protocols - therapeutic use (73) 73
cancer (71) 71
metastasis (69) 69
treatment outcome (65) 65
colorectal neoplasms - pathology (63) 63
bevacizumab (54) 54
aged, 80 and over (49) 49
camptothecin - analogs & derivatives (47) 47
survival (47) 47
care and treatment (45) 45
cetuximab (44) 44
prognosis (44) 44
patients (43) 43
disease-free survival (41) 41
fluorouracil - administration & dosage (41) 41
colorectal neoplasms - genetics (40) 40
metastases (40) 40
neoplasm metastasis (39) 39
oxaliplatin (37) 37
retrospective studies (36) 36
research (34) 34
tumors (34) 34
antineoplastic combined chemotherapy protocols - adverse effects (33) 33
fluorouracil (33) 33
camptothecin - administration & dosage (32) 32
irinotecan (32) 32
survival analysis (31) 31
antineoplastic combined chemotherapy protocols - administration & dosage (30) 30
colorectal carcinoma (30) 30
mutation (30) 30
therapy (30) 30
colorectal neoplasms - mortality (29) 29
leucovorin - administration & dosage (29) 29
5-fluorouracil (28) 28
antineoplastic agents - therapeutic use (28) 28
analysis (27) 27
neoplasm staging (26) 26
cancer therapies (25) 25
clinical trials (25) 25
drug therapy (25) 25
metastatic colorectal cancer (25) 25
pharmacology & pharmacy (24) 24
leucovorin (23) 23
1st-line treatment (22) 22
abridged index medicus (22) 22
cancer patients (22) 22
hematology, oncology and palliative medicine (22) 22
drug administration schedule (21) 21
genetic aspects (21) 21
health aspects (21) 21
organoplatinum compounds - administration & dosage (21) 21
trial (21) 21
adenocarcinoma - drug therapy (20) 20
cells (20) 20
deoxycytidine - analogs & derivatives (20) 20
expression (20) 20
antibodies, monoclonal, humanized (19) 19
disease progression (18) 18
kaplan-meier estimate (18) 18
liver neoplasms - secondary (18) 18
medicine & public health (18) 18
risk factors (18) 18
surgery (18) 18
angiogenesis (17) 17
biomarkers (17) 17
carcinoma (17) 17
fluorouracil - therapeutic use (17) 17
liver neoplasms - drug therapy (17) 17
proto-oncogene proteins p21 (17) 17
ras proteins - genetics (17) 17
receptor, epidermal growth factor - antagonists & inhibitors (17) 17
survival rate (17) 17
high level architecture (16) 16
liver metastases (16) 16
medicine, general & internal (16) 16
metastatic colorectal-cancer (16) 16
panitumumab (16) 16
phase-iii trial (16) 16
proto-oncogene proteins - genetics (16) 16
usage (16) 16
antibodies, monoclonal - administration & dosage (15) 15
camptothecin - therapeutic use (15) 15
deoxycytidine - administration & dosage (15) 15
lung neoplasms - drug therapy (15) 15
medical prognosis (15) 15
medical research (15) 15
patient outcomes (15) 15
prospective studies (15) 15
studies (15) 15
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Future Oncology, ISSN 1479-6694, 09/2016, Volume 12, Issue 18, pp. 2065 - 2069
Journal Article
Nature Medicine, ISSN 1078-8956, 07/2015, Volume 21, Issue 7, pp. 795 - 801
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1306 - 1315
Summary Background In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab significantly improved... 
Hematology, Oncology and Palliative Medicine | TRIAL | CETUXIMAB | SURROGATE | LEUCOVORIN | ONCOLOGY | END-POINT | PROGRESSION-FREE SURVIVAL | RAS MUTATIONS | GUIDELINES | KRAS | FLUOROURACIL | Leucovorin - administration & dosage | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Bevacizumab - therapeutic use | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Angiogenesis Inhibitors - administration & dosage | Neoplasm Metastasis | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Time Factors | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Angiogenesis Inhibitors - therapeutic use | Camptothecin - administration & dosage | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Bevacizumab - administration & dosage | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Proto-Oncogene Proteins - genetics | Treatment Outcome | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Intention to Treat Analysis | Italy | Aged | Infusions, Intravenous | Mutation | Colorectal Neoplasms - pathology | Antimitotic agents | Cancer patients | Care and treatment | Patient outcomes | Analysis | Colorectal cancer | Leucovorin | Metastasis | Antineoplastic agents | Index Medicus
Journal Article
Simulation Modelling Practice and Theory, ISSN 1569-190X, 12/2019, Volume 97
Modern Complex Engineered Systems (CES) are the result of the ever-growing advances in science and technology that involve new paradigms, architectures and... 
Distributed simulations | Functional mock-up interface (FMI) | Modeling methodologies | High level architecture (HLA)
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 937 - 948
Summary Background Tumour mutational status is an important determinant of the response of metastatic colorectal cancer to targeted treatments. However, the... 
Hematology, Oncology and Palliative Medicine | KRAS MUTATIONS | 1ST-LINE TREATMENT | LEUCOVORIN | PLUS IRINOTECAN | ONCOLOGY | RANDOMIZED PHASE-III | INHIBITS GROWTH | ACQUIRED-RESISTANCE | FLUOROURACIL | PLACEBO PLUS | TUMOR-GROWTH | Predictive Value of Tests | Proto-Oncogene Proteins p21(ras) | Colorectal Neoplasms - genetics | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Clinical Trials, Phase III as Topic | Time Factors | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Real-Time Polymerase Chain Reaction | Precision Medicine | Receptor, TIE-1 - blood | Phosphatidylinositol 3-Kinases - blood | Genetic Predisposition to Disease | Adenocarcinoma - blood | ras Proteins - blood | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Disease Progression | Phenotype | Class I Phosphatidylinositol 3-Kinases | Biomarkers, Tumor - genetics | ras Proteins - genetics | Patient Selection | DNA, Neoplasm - blood | Female | Adenocarcinoma - genetics | Retrospective Studies | Pyridines - therapeutic use | Colorectal Neoplasms - mortality | Colorectal Neoplasms - blood | Kaplan-Meier Estimate | Proportional Hazards Models | Phenylurea Compounds - therapeutic use | Proto-Oncogene Proteins B-raf - blood | Proto-Oncogene Proteins - genetics | Treatment Outcome | Randomized Controlled Trials as Topic | Biomarkers, Tumor - blood | Phosphatidylinositol 3-Kinases - genetics | Disease-Free Survival | Proto-Oncogene Proteins B-raf - genetics | Aged | DNA, Neoplasm - genetics | Colorectal Neoplasms - pathology | Proto-Oncogene Proteins - blood | Adenocarcinoma - mortality | Medical colleges | Medical research | Cancer patients | Prognosis | Liver | DNA | Colorectal cancer | Genetic research | Medicine, Experimental | Metastasis | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 12, pp. 1709 - 1719
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2014, Volume 371, Issue 17, pp. 1609 - 1618
In patients with metastatic colon cancer, fluorouracil, oxaliplatin, and irinotecan plus bevacizumab, as compared with fluorouracil and irinotecan plus... 
1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | INFUSIONAL FLUOROURACIL | LEUCOVORIN | MANAGEMENT | PHASE-III | GUIDELINES | IRINOTECAN | OXALIPLATIN | CHEMOTHERAPY | FOLFIRI | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Bevacizumab | Fluorouracil - therapeutic use | Antibodies, Monoclonal, Humanized - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Neoplasm Metastasis - drug therapy | Colorectal Neoplasms - drug therapy | Adult | Female | Leucovorin - therapeutic use | Liver Neoplasms - secondary | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Camptothecin - therapeutic use | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Colorectal Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Organoplatinum Compounds - adverse effects | Treatment outcome | Care and treatment | Analysis | Colorectal cancer | Dosage and administration | Leucovorin | Fluorouracil | Colorectal carcinoma | Diarrhea | Metastasis | Survival | Patients | Clinical outcomes | Metastases | Irinotecan | Stomatitis | Chemotherapy | Neurotoxicity | Oxaliplatin | Monoclonal antibodies | Vascular endothelial growth factor | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 9, pp. 845 - 852
Summary Background The FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) regimen has been shown to be better than FOLFIRI (fluorouracil,... 
Hematology, Oncology and Palliative Medicine | LIVER METASTASES | INFUSIONAL FLUOROURACIL | LEUCOVORIN | K-RAS | PLUS IRINOTECAN | ONCOLOGY | CLINICAL-TRIALS | TUMOR RESPONSE | ORAL FLUOROPYRIMIDINES | BICC-C | CHEMOTHERAPY | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Bevacizumab | Antibodies, Monoclonal, Humanized | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Kaplan-Meier Estimate | Adenocarcinoma - drug therapy | Disease-Free Survival | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Organoplatinum Compounds - adverse effects | Adenocarcinoma - mortality | Chemotherapy | Oncology, Experimental | Colorectal cancer | Clinical trials | Metastasis | Research | Angiogenesis inhibitors | Drug therapy | Cancer | Medical research | Analysis | Medicine, Experimental | Index Medicus
Journal Article
Scientific Reports, ISSN 2045-2322, 12/2015, Volume 5, Issue 1, pp. 18670 - 18670
Journal Article